Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Observational Secukinumab Data Reflect Clinical Trial Results in Patients With Moderate to Severe Psoriasis

Publish date:: November 9, 2019

Key clinical point: Observational data support the safety and effectiveness of secukinumab for psoriasis in real-world settings.

Major finding: By week 24, 86% achieved a 75% improvement on the Psoriasis Area and Severity Index (PASI 75), 68.5% a PASI 90, and 39.7% a PASI 100.

Study details: The interim analysis of 1,988 psoriasis patients treated with secukinumab in an observational 24-week study conducted in Germany.

Disclosures: The study was funded by Novartis, Germany. Four authors are employees of the company. The lead author has served as an investigator and/or consultant for multiple pharmaceutical companies, including Novartis, AbbVie, Amgen, Arena, Biogen Idec, Boehringer Ingelheim, and Celgene. Other authors also disclosed serving as investigators, consultants, and/or speakers for Novartis and other companies.

Citation:

Thaci D et al. J Eur Acad Dermatol Venereol. 2019 Sep 21. doi: 10.1111/jdv.15962.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Psoriasis

Synovial, skin gene expression differences may explain PsA treatment responses,

Tildrakizumab for psoriasis shows durable efficacy over 5 years,

Non-Whites remain sorely underrepresented in phase 3 psoriasis trials,

Study highlights differences between White and Latino patients with psoriasis,

Shingrix effective in older adults with preexisting immune-mediated disorders,